This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Santa Clara, CA-based Agilent Technologies, Inc. was originally a spin-off from Hewlett-Packard. The company is an original equipment manufacturer (OEM) of a broad-based portfolio of test and measurement products serving multiple end markets. The company has three business segments, including Life Sciences & Applied Markets Group (LSAG), Diagnostics and Genomics Group (DGG) and Agilent Cross Lab Group (ACG). The company uses a direct sales model for the distribution of its products, which is supplemented by distributors, resellers, manufacturers’ representatives, telesales and electronic commerce.
What's in Store for Cloudflare (NET) This Earnings Season?
by Zacks Equity Research
Cloudflare's (NET) Q4 results are likely to reflect benefits from its diversified customer base. However, uncertainty related to the coronavirus crisis remains a concern.
What's in Store for Paycom (PAYC) This Earnings Season?
by Zacks Equity Research
Paycom's (PAYC) Q4 results are likely to reflect benefits from new business wins and market share gains.
Tyler (TYL) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Expanding margins are likely to have aided Tyler's (TYL) Q4 performance. However, revenues are likely to have been negatively impacted by the pandemic as well as a recent security breach.
Why Agilent (A) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Agilent (A) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Is Agilent (A) Up 2.4% Since Last Earnings Report?
by Zacks Equity Research
Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Greif (GEF) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Greif's (GEF) Q4 results are likely to reflect benefits from cost-cutting efforts and the Caraustar buyout.
Macy's, Target, Gap and Best Buy are part of Zacks Earnings Preview
by Zacks Equity Research
Macy's, Target, Gap and Best Buy are part of Zacks Earnings Preview
Agilent's (A) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Agilent Technologies' (A) fiscal fourth-quarter results reflect growth in all the segments and regions served.
Agilent Technologies (A) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Agilent (A) delivered earnings and revenue surprises of 7.69% and 6.25%, respectively, for the quarter ended October 2020. Do the numbers hold clues to what lies ahead for the stock?
Agilent (A) Hikes Dividend to 19.4 Cents, Rewards Shareholders
by Zacks Equity Research
Agilent (A) hikes dividend to 19.4 cents per share in a bid to reward shareholders.
The Retail Sector's Strong Earnings Performance
by Sheraz Mian
The common view about the Retail sector is a space that has been particularly hit hard by the Covid-19 pandemic. But that's hardly the full story...
What's in the Offing for Agilent (A) This Earnings Season?
by Zacks Equity Research
Agilent's (A) strength in revenue segments is likely to reflect on fiscal fourth-quarter results. However, the global coronavirus-driven economic crisis may have been a woe.
Agilent Gets Expanded FDA Approval for pharmDX Assay in U.S.
by Zacks Equity Research
Agilent Technologies (A) gets FDA Approval for PD-L1 IHC 22C3 pharmDx assay, thereby further strengthening presence in the companion diagnostics market.
Agilent Technologies (A) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Agilent (A) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Testing Equipment Stocks to Escape a Challenging Industry
by Zacks Equity Research
Coronavirus-imposed economic turbulences are stressing the Zacks Electronics - Testing Equipment industry. However, industry players like TER, AME, CGNX and NATI are set to gain from 5G prospects.
Expedia Group's (EXPE) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Expedia Group's (EXPE) third-quarter results are expected to reflect benefits from improving travel trends. However, coronavirus woes might have remained headwinds.
Jack Henry (JKHY) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Jack Henry's (JKHY) first-quarter fiscal 2021 results are likely to reflect strength across Core, Payments and Complementary segments amid coronavirus woes.
What's in the Cards for MercadoLibre (MELI) in Q3 Earnings?
by Zacks Equity Research
MercadoLibre's (MELI) third-quarter results are likely to reflect benefits from its e-commerce, logistics and fintech offerings.
Why Agilent (A) Could Beat Earnings Estimates Again
by Zacks Equity Research
Agilent (A) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Truth About Market Timing - October 05, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
Nike, OrganiGram, Thermo Fisher, Danaher Corp and Agilent Tech highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Nike, OrganiGram, Thermo Fisher, Danaher Corp and Agilent Tech highlighted as Zacks Bull and Bear of the Day
3 Picks to Ride the Coronavirus-Led Strength in Lab Plastic Space
by Urmimala Biswas
These laboratory equipment suppliers' fate does not depend on the end result of the R&D outcomes of the drug and vaccine makers.
Agilent (A) Up 2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Keys to Successfully Timing the Markets - September 11, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
Agilent's (A) Q3 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Agilent Technologies' (A) fiscal third quarter results reflect growth in pharmaceutical and food market. However, COVID-19 headwinds were concerns.